home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

162.33 -5.60 (-3.33%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Reviewing Mailbag Items and 5 Stocks Indistinguishable From Magic ↗

October 07, 2023

September wasn't a good month for the stock market, but there's plenty for investors to talk about.

Via The Motley Fool

Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors ↗

September 26, 2023

Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.

Via Benzinga

What 6 Analyst Ratings Have To Say About Repligen ↗

September 06, 2023

Via Benzinga

Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗

August 02, 2023

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Wednesday. Here are some big stocks recording gains in today’s session. Powell Industries, Inc. (NASDAQ: POWL) shares jumped...

Via Benzinga

What 4 Analyst Ratings Have To Say About Repligen ↗

July 06, 2023

Via Benzinga

Looking Into Repligen's Return On Capital Employed ↗

May 08, 2023

Via Benzinga

Why Repligen Stock Is Sinking Today ↗

April 25, 2023

Investors appear to be anticipating an underwhelming first-quarter report from the bioprocessing company.

Via The Motley Fool

Top 5 Health Care Stocks That May Collapse In July ↗

July 24, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2023 ↗

July 20, 2023

Via Benzinga

Why Shares of Repligen Rose This Week ↗

January 12, 2023

The company is coming off a solid third quarter and is getting noticed by analysts.

Via The Motley Fool

Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock ↗

December 07, 2022

Via Benzinga

Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact ↗

September 20, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023 ↗

July 06, 2023

Via Benzinga

Over $6M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying ↗

May 09, 2023

Although US stocks closed mixed on Monday, there were a few notable insider trades.

Via Benzinga

Repligen Expects Slower Growth In APAC, Builds Portfolio On Heels Of FlexBiosys Deal ↗

May 02, 2023

Repligen Corp (NASDAQ: RGEN) reported Q1 FY23 sales of $182.66 million, down 12% Y/Y as reported,

Via Benzinga

This Analyst Is Bullish on Repligen's FlexBiosys Acquisition for Fluid Management Portfolio ↗

April 12, 2023

Repligen Inc (NASDAQ: RGEN) agreed to acquire FlexBiosys Inc to build its Fluid Management franchise and add a full range of single-use bioprocessing bags and assemblies.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗

March 28, 2023

Via Benzinga

Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover ↗

February 06, 2023

Danaher is reportedly looking to add to its wheelhouse to compete with Thermo.

Via Investor's Business Daily

Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday ↗

January 30, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Earnings Scheduled For February 22, 2023 ↗

February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Repligen Earnings Perspective: Return On Capital Employed ↗

November 09, 2022

Pulled from Benzinga Pro data, Repligen (NASDAQ:RGEN) posted Q3 earnings of $40.41 million, an increase from Q2 of 18.96%. Sales dropped to $200.74 million, a 3.32% decrease between quarters.

Via Benzinga

Recap: Repligen Q3 Earnings ↗

November 01, 2022

Repligen (NASDAQ:RGEN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Repligen beat estimated earnings by...

Via Benzinga

Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday ↗

October 20, 2022

Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of...

Via Benzinga

Earnings Scheduled For November 1, 2022 ↗

November 01, 2022

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.

Via Benzinga

Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session ↗

October 19, 2022

Gainers SenesTech, Inc. (NASDAQ: SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share.

Via Benzinga

Abbott Laboratories, M&T Bank And Some Other Big Stocks Moving Lower On Wednesday ↗

October 19, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

MarketBeat: Week in Review 9/12 – 9/16

September 16, 2022

In volatile markets, rely on MarketBeat to keep you focused on your investment objectives. Here are some of our most popular articles from this week

Via MarketBeat

Topics Economy

Why Medical Products Maker Repligen May Be A Potential Buy

September 15, 2022

Medical products maker Repligen has a long history of trouncing sales and earnings views, and it just boosted its full-year sales guidance. Is the stock a buy?

Via MarketBeat

Top-Rated Stocks: Lantheus Stock Sees Composite Rating Climb To 96 ↗

September 01, 2022

Top-rated Lantheus stock saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com